Trial Profile

A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Levofolinic acid (Primary) ; Oxaliplatin (Primary) ; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Therapeutic Use
Acronyms NEOPAN; PRODIGE 29 - UCGI 26 - NEOPAN

Most Recent Events

08 Jan 2024 Status changed from active, no longer recruiting to completed.
24 Oct 2023 Results assessing quality of life of patients treated with with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma presented at the 48th European Society for Medical Oncology Congress
13 Oct 2023 Planned End Date changed from 1 Jan 2027 to 1 Nov 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com